A Major Endogenous Ligand Substance Involved in Renal Failure

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The clinical significance of a major endogenous ligand substance, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), present in the sera of patients with renal failure, was examined. In patients with chronic renal failure, the serum CMPF concentration was correlated with the serum creatinine concentration, but not in patients with acute renal failure. The accumulation of CMPF in the sera of patients with chronic renal failure may reflect the ‘chronicity’ of renal failure. Plasma exchange was more effective than direct hemoperfusion for the elimination of CMPF retained in uremic serum.

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEF

Journal ID (nlm-ta): Nephron

Journal ID (doi): 10.1159/issn.1660-8151

Title: Nephron

Publisher: S. Karger AG

ISSN (Print): 1660-8151

ISSN (Electronic): 2235-3186

Publication date Subscription-year: 1988

Publication date (Print): 1988

Publication date (Electronic): 09 December 2008

Volume: 49

Issue: 4

Pages: 277-280

Affiliations

Department of Internal Medicine and Nephrology, Nishijin Hospital, Kyoto, Japan

Article

Publisher ID: 185075 Other ID: Nephron 1988;49:277–280

DOI: 10.1159/000185075

PubMed ID: 3412543

SO-VID: 96e49fa7-c0d7-47a8-9842-66cd4f5446eb

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date accepted : 02 October 1987

Page count

Pages: 4

Comments

Comment on this article

scite_

Cited by 1

Dithymoquinone as a novel inhibitor for 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) to prevent renal failure
Authors: Muniba Faiza, Prof. Yonghua Wang, Tariq Abdullah

See all cited by

- Version 1

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before July 31, 2024